29 completed, 6 terminated, 2 unknown, 1 suspended. 21 Phase 1, 20 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 16, Terminated 2, Unknown 2, Suspended 1 |
| Phase 2 | 20 | Completed 17, Terminated 3 |
| Phase 3 | 3 | Terminated 3 |
Follow Synta Pharmaceuticals Corp.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ganetespib Window of Opportunity Study in Head and Neck Cancers Ganetespib, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis - Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Emory University | 3 | 2014-12-01 | 2016-07-26 |
| A Phase I/II Study of Ganetespib in Combination With Doxorubicin Ganetespib, Doxorubicin - Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Georgetown University | 11 | 2014-10-01 | 2018-04-23 |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer ganetespib, paclitaxel, trastuzumab - HER2-positive Breast Cancer, Male Breast Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 9 | 2014-04-01 | 2018-06-14 |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) ganetespib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 20 | 2013-12-01 | 2019-05-15 |
| A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Docetaxel, Ganetespib - Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB | Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 696 | 2013-04-01 | 2016-07-01 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer ganetespib - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 51 | 2012-07-01 | 2015-11-05 |
| Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer capecitabine + ganetespib - Rectal Cancer | Phase 1 | Completed | Emory University | 16 | 2012-05-01 | 2016-02-22 |
| A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Ganetespib - Non Small Cell Lung Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 12 | 2012-04-01 | 2015-05-20 |
| A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Ganetespib, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Emory University | 8 | 2012-01-01 | 2015-10-12 |
| STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma STA-9090 - Melanoma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 3 | 2011-09-01 | 2017-04-12 |
| Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Docetaxel, Combination of ganetespib and docetaxel - Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 / Phase 3 | Terminated | Synta Pharmaceuticals Corp. | 385 | 2011-05-01 | 2015-11-05 |
| Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer STA-9090 - Breast Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2011-01-01 | 2015-11-20 |
| Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia Elesclomol Sodium - Acute Myeloid Leukemia | Phase 1 | Unknown | Synta Pharmaceuticals Corp. | 36 | 2011-01-01 | 2014-02-03 |
| STA-9090(Ganetespib) in Metastatic Ocular Melanoma STA-9090 - Ocular Melanoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 17 | 2010-09-17 | 2018-10-18 |
| STA-9090 in Patients With Advanced Hepatocellular Cancer STA-9090 - Hepatocellular Carcinoma | Phase 1 | Completed | Massachusetts General Hospital | 16 | 2010-08-01 | 2018-04-25 |
| STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer STA-9090 - Esophagogastric Cancer | Phase 2 | Completed | Massachusetts General Hospital | 28 | 2010-08-01 | 2023-11-02 |
| Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer STA-9090 - Small Cell Lung Cancer | Phase 2 | Completed | David M. Jackman, MD | 25 | 2010-07-28 | 2019-04-16 |
| A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors STA-9090 (ganetespib) with Docetaxel - Solid Tumor Malignancies | Phase 1 | Completed | Synta Pharmaceuticals Corp. | 27 | 2010-07-01 | 2014-09-19 |
| Clinical and Translational Study of STA-9090 STA-9090 - Colon Cancer, Rectal Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 20 | 2010-04-01 | 2015-11-20 |
| A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Ganetespib - Gastrointestinal Stromal Tumor | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 27 | 2010-01-01 | 2016-03-10 |
Showing 20 of 38. Sign in to see all of them.
Neoplasm Metastasis (7) · Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (3) · Crohn Disease (3) · Melanoma (3) · Hematologic Neoplasms (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Rectal Neoplasms (2) · Recurrence (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Blast Crisis (1)
STA 9090 (23) · Paclitaxel (4) · apilimod (4) · elesclomol (4) · Docetaxel (3) · Bortezomib (1) · Calcium Dobesilate (1) · Capecitabine (1) · Carboplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Sirolimus (1) · Taxes (1) · Trastuzumab (1) · pertuzumab (1)
United States (36) · Canada (7) · Spain (4) · United Kingdom (4) · Belgium (3) · Germany (3) · Romania (3) · Bosnia and Herzegovina (2) · Croatia (2) · Czechia (2) · Netherlands (2) · Poland (2) · Russia (2) · Serbia (2) · Argentina (1)
Shanu Modi, MD (2) · AeRang Kim, MD, PhD (1) · Andrea Cercek, MD (1) · Andrew Zhu, MD (1) · Bassel El-Rayes, MD (1) · Brigitte Widemann, MD (1) · Bruce Sands, MD (1) · David Jackman, MD (1) · F. Stephen Hodi, M.D. (1) · F. Stephen Hodi, MD (1) · Giuseppe Giaccone, MD PhD (1) · Jeffrey W Clark, MD (1) · Nabil F. Saba, MD (1) · Peter Mannon, MD (1) · Sagar Lonial, MD (1)
PMID 22170479, PMID 23401447, PMID 23530663, PMID 23838996, PMID 28764748, PMID 29594044, PMID 31898183, PMID 32089640